$PSTV I have added to my portfolio at $0.46. Target price is $8 according to analysts.

I also wrote articles on $AtaiLifeSince and Immunic at under 1$. It's good if you know the industry professionally.

Average rating: Buy

Target price: 8,0000 $

Implied return

Analysts 4

Last Updated 09-oct-2025

Analysts breakdown

Buy 4

Overweight 0

Hold 0

Underweight 0

Sell 0

🧬 What does Plus Therapeutics do?

• PSTV is a clinical-stage biopharmaceutical company (USA) specializing in targeted radiotherapeutics and diagnostics for brain/CNS cancers (CNS cancers). National Law Review+3Plus Therapeutics+3Investors Hangout+3
• They have developed the product REYOBIQ™which is being tested in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Investors Hangout+2Plus Therapeutics+2
• In parallel, the diagnostic tool CNSide a cerebrospinal fluid-based (CSF) assay test procedure for the identification and tracking of tumor cells in the brain/CNS. National Law Review+1

🚀 What are the most important "catalysts" / positive signals?

Accreditation / certification for CNSide Lab

The Houston lab has received CLIA certification, which is a necessary step to roll out the test commercially in the US and enable reimbursement by Medicare / Medicaid / private insurers. GlobeNewswire

Financing & Capital Structure

• They raised $15m in March 2025 and later restructured the financing to reduce or eliminate potentially highly dilutive aspects (warrants, etc.). Plus Therapeutics+2Nasdaq+2
• They have met Nasdaq minimum capital requirements and are not under threat of listing. Nasdaq+1

Clinical progress at REYOBIQ

• Phase 1 clinical data (safety & efficacy) look promising according to the company. Investors Hangout+1
• Trials for LM & GBM are ongoing and new research/trial sites are being added. Investors Hangout+1

Market opportunity

• Test markets for CNSide are large: many cases of leptomeningeal metastases, high medical need profile. National Law Review+1
• National reimbursement agreement with UnitedHealthcare (UNH) for CNSide likely (or already partially implemented) - big step towards recurring revenues. Reddit+1

⚠️ Main challenges & risks

For the potential to become real, some critical points need to be considered:

• Cash burn & financial stability
• Large losses, high research and development costs, high administrative costs. StockInvest+2Plus Therapeutics+2
• Regulatory hurdles
• Approvals, laboratory compliance, reimbursement by insurers and Medicare, etc. If expectations are not met or negotiations stall, this can be very detrimental.
• Dilution
• Despite restructuring, there is a risk that further capital will be required. If this happens, shareholders could be diluted. Nasdaq+2Plus Therapeutics+2
• Market resistance / competition
• Other diagnostics or therapeutics companies with more resources could be faster. Techniques or alternative therapies (non-radioactive or non-invasive) could also bring competition.
• Balance sheet / listing regulations
• PSTV has already had to solve problems with Nasdaq requirements (minimum equity, minimum share price, etc.). Such issues can cause abrupt pressure. Investing.com+1

🎯 Valuation: Why many investors believe in Plus Therapeutics

• Because CSTside is the first commercial product approach that comes relatively close to revenue - this shifts PSTV from pure speculation to potential revenue generation.
• Because clinical data on REYOBIQ already show positive signals: safety, feasibility, possibly efficacy - if confirmed in next phases, this could drive value strongly.
• Because the capital structure has been improved and the risk of massive dilution has been somewhat mitigated by the financing restructuring.